• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)].

作者信息

Huang X, Guo N, Fan Y

机构信息

Institute of Hematology, Beijing Medical University.

出版信息

Zhonghua Zhong Liu Za Zhi. 1995 Jan;17(1):64-6.

PMID:7656793
Abstract

One hundred sixteen cases of leukemia patients received supra-high single dose TBI for bone marrow transplantation (BMT) with total a radiation dosage of 700-770 Gy at about 5cGy/min. Seventy patients were given ondanstron (8mg) plus dexamethasone (DXM, 10mg) for prophylaxis of TBI-induced acute nausea and vomiting, 46 patients were given paspertin (10mg) plus dexamethasone (10mg) as controls. The clinical results showed that ondansetron plus DXM achieved complete or major control of vomiting in 59/70 (84%) of cases and there was little or no nausea in 61/70 (87%), while paspertin plus DXM achieved complete or major control of vomiting only in 9/46 (20%) of cases and little or no nausea in 5/46 (11%). It is concluded that ondansetron has significantly greater advantage over paspertin in the control of acute emesis induced by TBI.

摘要

相似文献

1
[Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)].
Zhonghua Zhong Liu Za Zhi. 1995 Jan;17(1):64-6.
2
[Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].[昂丹司琼在单次分割照射治疗患者中预防放射性恶心和呕吐的作用]
Srp Arh Celok Lek. 1996 May-Jun;124(5-6):131-4.
3
Radiation-induced emesis: effects of ondansetron.辐射诱发的呕吐:昂丹司琼的作用
Semin Oncol. 1992 Dec;19(6 Suppl 15):38-43.
4
[Acute tolerance in hyperfractionated accelerated whole-body irradiation].[超分割加速全身照射中的急性耐受性]
Strahlenther Onkol. 1996 Dec;172(12):685-9.
5
Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.口服格拉司琼与口服昂丹司琼预防超分割全身照射患者恶心和呕吐的疗效与安全性的双盲、随机、平行组研究
Bone Marrow Transplant. 2000 Jul;26(2):203-10. doi: 10.1038/sj.bmt.1702479.
6
Ondansetron for efficient emesis control during total body irradiation.
Bone Marrow Transplant. 1994 Feb;13(2):169-71.
7
Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children.昂丹司琼用于治疗儿童化疗和放疗引起的呕吐的止吐疗法。
N Z Med J. 1992 Sep 23;105(942):369-71.
8
A review of ondansetron in the management of radiotherapy-induced emesis.昂丹司琼用于治疗放疗引起的呕吐的综述。
Oncology. 1993 May-Jun;50(3):173-9. doi: 10.1159/000227173.
9
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.格拉司琼联合地塞米松对接受化疗和全身照射的骨髓移植患者的止吐疗效。
Bone Marrow Transplant. 1999 Feb;23(3):265-9. doi: 10.1038/sj.bmt.1701565.
10
Is veno-occlusive disease incidence influenced by the total-body irradiation technique?全身照射技术会影响静脉闭塞性疾病的发病率吗?
Strahlenther Onkol. 1995 Dec;171(12):694-7.

引用本文的文献

1
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.2016年更新的MASCC/ESMO共识建议:预防放疗引起的恶心和呕吐。
Support Care Cancer. 2017 Jan;25(1):309-316. doi: 10.1007/s00520-016-3407-8. Epub 2016 Sep 13.
2
Prophylactic Management of Radiation-Induced Nausea and Vomiting.放射性恶心和呕吐的预防性管理
Biomed Res Int. 2015;2015:893013. doi: 10.1155/2015/893013. Epub 2015 Sep 3.
3
Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.
放疗所致恶心呕吐(RINV):MASCC/ESMO 放疗止吐治疗指南:2009 年更新。
Support Care Cancer. 2011 Mar;19 Suppl 1:S5-14. doi: 10.1007/s00520-010-0950-6. Epub 2010 Aug 10.